Substance-induced psychoses: A critical review of the literature

Current Drug Abuse Reviews

Volumn 4, Issue 4, 2011, Pages 228-240

  Fiorentini, Alessio ^a   Volonteri, Lucia Sara ^b   Dragogna, Filippo ^a   Rovera, Chiara ^a   Maffini, Michele ^a   Mauri, Massimo Carlo ^a   Altamura, Carlo A ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Amphetamines; Cannabis; Cocaine; Drug abuse; Schizophrenia; Substance induced psychosis

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; CANNABINOID; CANNABIS; COCAINE; DRONABINOL; KETAMINE; METHAMPHETAMINE; PHENCYCLIDINE; PLACEBO;

CHRONIC DRUG ADMINISTRATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MISUSE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GOOD CLINICAL PRACTICE; HUMAN; NEUROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SUBSTANCE ABUSE;

EID: 83455220555     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/1874473711104040228     Document Type: Review

References (187)

1. Olfson M, Lewis-Fernandez R, Weissman MM, et al. Psychotic symptoms in an urban general medicine practice. Am J Psychiatry 2002; 159: 1412-9.
2. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511-8.
3. Cantor-Graae E, Nordstrom LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 2001; 48: 69-82.
4. Young D, Serorille WB. Paranoid psychosis in narcolepsy and possible dangers of Benzedrine treatment. Med Clin North Am 1938; 22: 637-43.
5. Calello DP, Osterhoudt KC. Acute psychosis associated with therapeutic use of dextroamphetamine [Letter to the Editor]. Pediatrics 2004; 113: 1466.
6. Surles LK, May HJ, Garry JP. Adderall-induced psychosis in an adolescent. J Am Board Fam Pract 2002; 15: 498-500.
7. Schuckit MA. Drug and Alcohol Abuse. 3rd ed. New York, NY: Plenum Publishing Corp 1989.
8. Lowestein DH, Massa SM, Rowbotham MC, et al. Acute neurologic and psychiatric complications associated with cocaine abuse. Am J Med 1987; 83: 841-6.
9. Ries RK. The dually diagnosed patient with psychotic symptoms. J Addict Dis 1993; 12: 103-22.
10. McLellan AT, Woody GE, O'Brien CP. Development of psychiatric illness in drug abuse: possible role of drug preference. N Engl J Med 1979; 301: 1310-4.
11. Angrist B. Amphetamine psychosis: clinical variations of the syndrome. In: Cho AK, Segal DS, Eds. Amphetamine and its analogs. Orlando, Fla: Academic Press In; 1994; pp. 387-414.
12. Freedman DX. On the use and abuse of LSD. Arch Gen Psychiatry 1968; 18: 330-47.
13. Vardy MM, Kay SR. LSD psychosis or LSD-induced schizophrenia: a multimethod inquiry. Arch Gen Psychiatry 1983; 40: 883-7.
14. Chopra GS, Smith JW. Psychotic reactions following cannabis use in East Indians. Arch Gen Psychiatry 1974; 30: 24-7.
15. Oliver DH, Kapur S. The dopamine hyphotesis of schizophrenia: version III-The final common pathway. Schizophr Bull 2009; 35: 549-62.
16. Ritz MC, Lamb RJ, Goldberg SR, et al. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987; 237(4819): 1219-23.
17. Fergusson DM, Poulton R, Smith PF, et al. Cannabis and psychosis. BMJ 2006; 332: 172-5.
18. Howlett AC, Breivogel CS, Childers CR. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 47: 345-58.
19. Heikkila RE, Orlansky H, Cohen G. Studies on the distinction between uptake inhibition and release of (3H) dopamine in rat brain tissue slices. Biochem Pharmacol 1975; 24: 847-52.
20. Saunders C, Ferrer JV, Shi L, et al. Amphetamine-induced loss of human dopamine transporter activity; an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA 2000; 97: 6850-5.
21. Snyder SH. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry 1976; 133: 197-202.
22. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 2000; 48: 627-40.
23. Wanat MJ, Willuhn I, Clark JJ, et al. Phasic dopamine release in appetitive behaviors and drug addiction. Curr Drug Abuse Rev 2009; 2(2): 195-213
24. Rosenthal RN, Miner CR. Differential diagnosis of substanceinduced psychosis and schizophrenia in patients with substance use disorder. Schizophr Bull 1997; 23: 187-93.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Editions, Text Revision, Washington, DC: American Psychiatric Association 2000.
26. Fenning S, Bromet EJ, Craig T, et al. Psychotic patients with unclear diagnoses: a descriptive analysis. J Nerv Ment Dis 1995; 183: 207-13
27. Schuckit MA. Comorbidity between substance use disorders and psychiatric conditions. Addiction 2006; 101 (suppl 1): 76-88.
28. Chen CK, Lin SK, Sham PC, et al. Premorbid characteristics and comorbidity of methamphetamine users with and without psychosis. Psychol Med 2003; 33: 1407-14.
29. Iwanami A, Sugiyama A, Kuroki N, et al. Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan: a preliminary report. Acta Psychiatr Scand 1994; 89: 428-32.
30. Rounsaville BJ. DSM-V Research Agenda: Substance Abuse/Psychosis Comorbidity. Schizophr Bull 2007; 4: 947-52.
31. Mathias S, Lubman DI, Hides L. Substance-induced psychosis: a diagnostic conundrum. J Clin Psychiatry 2008; 69: 358-67.
32. Johnston LD, O'Malley PM, Bachman JG, et al. Monitoring the Future National Survey Results on Drug Use, 1975-2004, Vol 1: Secondary School Students (NIH Publication N0.05-5727). Bethesda, Md: National Institute on Drug Abuse 2005; p. 520.
33. European Monitoring Center on Drugs Addition. Annual Report 2006: The State of the Drugs Problem in Europe. Lisbon, Portugal: European Monitoring Center on Drugs and Drug Addition 2006.
34. Australian Institute of Health and Welfare. 2004 National Drug Strategy Household Survey: First Results. Canberra, Australia: Australian Institute of Health and Welfare; 2005. AIHW Cat No. PHE 57. AIHW (Drug Statistics Series No.13).
35. Monshouwer K, Smit F, de Graaf R, et al. First cannabis use: does onset shift on younger ages? Findings from 1988 to 2003 from the Dutch National School Survey on Substance Use. Addiction 2005; 100: 963-70.
36. Hall WD. Cannabis use and mental health of young people. Aust NZ J Psychiatry 2006; 40: 105-113.
37. Hall W, Swift W. The THC content of cannabis in Australia: evidence and implication. Aust NZ J Public Health 2000; 24: 503-8.
38. Pijlman FT, Rigter SM, Hoek J, et al. Strong increase in total delta -THC in cannabis preparations sold in Dutch coffee shop. Addict Biol 2005; 10: 171-80.
39. Swendsen J, Conway KP, Degenhardt L, et al. Mental disorders as risk factors for substance use, abuse, and dependence: results from the 10-year follow up of the National Comorbidity Survey. Addiction 2010; 105(6): 1117-28
40. Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug Abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2007; 64(5): 566-76
41. Smith MJ, Thirthalli J, Abdallah AB, et al. Prevalence of psychotic symptoms in substance users: a comparison across substances. Compr Psychiatry 2009; 50: 245-50.
42. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiological Catchment Area (ECA) study. JAMA 1990; 264: 2511-8.
43. Jablensky A, McGrath J, Herrman H, et al. Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders. Aust N Z J Psychiatry 2000; 34: 221-36.
44. Rabinowits J, Bromet EJ, Lavelle J, et al. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychol Med 1998; 28: 1411-9.
45. Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Act Psychiatr Scand 2005; 112: 141-8.
46. Mauri MC, Volonteri LS, De Gaspari IF, et al. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin Pract Epidemiol Ment Health 2006; 2: 1-8.
47. Strakowski SM, Tohen M, Stoll AL, et al. Comorbidity in psychosis at first hospitalization. Am J Psychiatry 1993; 150: 752-7.
48. Swanson JW, Swartz MS, Essock SM, et al. The socioenvironmental context of violent behaviour in persons treated for severe mental illness. Am J Public Health 2002; 92: 1523-31.
49. Mendoza R, Miller BL, Mena I. Emergency room evaluation of cocaine-associated neuropsychiatric disorders. In: Galenter M, Ed. Recent Developments in Alcoholism: Alchol and Cocaine: Similarities and Differences. Vol 10. New York, NY: Plenum Pless Inc 1992; pp. 73-86.
50. Boutros N, Bowers MB. Chronic substance-induced psychotic disorders: state of the literature. J Neuropsychiatr Clin Neurosci 1996; 8: 262-9.
51. Drake RJ, Dunn G, Terrier N, et al. The evolution of symptoms in early corse of non-affective psychosis. Schizophr Res 2003; 63: 171-9.
52. Caton CLM, Drake RE, Hasin DS, et al. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Arch Gen Psychiatry 2005: 137-45.
53. Caton CLM, Hasin DS, Shrout PE, et al. Stability of early-phase primary psychotic disorders with concurrent substance-induced psychosis. Br J Psychiatry 2007; 190: 105-11.
54. Wilson N, Cadet JL. Comorbid mood, psychosis, and marijuana abuse disorders: a theoretical review. J Addict Dis 2009; 28(4): 309-19.
55. Basavarajappa BS. Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Curr Neuropharmacol 2007; 5(2): 81-97.
56. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neurosci 1997; 77(2): 299-318.
57. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 2005; 7: 625-54
58. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54(2): 161-202.
59. D'Souza DC, Braley G, Blasie R, et al. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humans. Psychopharmacol 2008; 198(4): 587-603.
60. Herman H, Marsicano G, Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002; 109(3): 451-60.
61. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 2007; 8(11): 885-95
62. Di Marzo V, Ligresti A, Morera E, Nalli M, Ortar G. The anandamide membrane transporter. Structure-activity relationships of anandamide and oleoylethanolamine analogs with phenyl rings in the polar head group region. Bioorg Med Chem 2004; 12(19): 5161-9
63. Morrison PD, Murray RM. From real-world events to psychosis: the emerging neuropharmacology of delusions. Schizophr Bull 2009; 35(4): 668-74
64. Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001; 178: 116-22.
65. Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry 1993; 163: 141-9.
66. Leweke FM, Schneider U, Thies M, et al. Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacol (Berl) 1999; 142(3): 230-5.
67. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9- tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57: 594-608
68. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264(19): 2511-8.
69. Hambrecht M, Häfner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry 1996; 40(11): 1155-63.
70. Hambrecht M, Häfner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust N Z J Psychiatry 2000; 34(3): 468-75.
71. Arseneault L, Cannon M, Poulton R, et al. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325(7374): 1212-3.
72. Zammit S, Allebeck P, Andreasson S, et al. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002; 325: 1199.
73. Corcoran CM, Kimhy D, Stanford A, et al. Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophr Res 2008; 106(2-3): 286-93.
74. Cuffel BJ, Heithoff KA, Lawson W. Correlates of patterns of substance abuse among patients with schizophrenia. Hosp Commun Psychiatry 1993; 44(3): 247-51.
75. Kendler KS, Gallagher TJ, Abelson JM, et al. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch Gen Psychiatry 1996; 53(11): 1022-31.
76. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370 (9584): 319-28.
77. Murrey GJ, Dallas R, Maki A. History of reported head trauma in a sample of women in substance abuse treatment. Am J Drug Alcohol Abuse 2007; 33(2): 327-32.
78. Phillips LJ, Curry C, Yung AR, et al. Cannabis use is not associated with the development of psychosis in an "ultra" highrisk group. Aust N Z J Psychiatry 2002; 36(6): 800-6
79. Arseneault L, Cannon M, Witton J, et al. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184: 110-7.
80. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005; 19(2): 187-94.
81. Smit F, Bolier L, Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. Addiction 2004; 99(4): 425-30.
82. Weiser M, Davidson M, Noy S. Comments on risk for schizophrenia. Schizophr Res 2005; 79(1): 15-21.
83. Haroun N, Dunn L, Haroun A, et al. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull 2006; 32(1): 166-78.
84. Hides L, Dawe S, Kavanagh DJ, et al. Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br J Psychiatry. 2006; 189: 137-43.
85. Pencer A, Addington J. Substance use and cognition in early psychosis. Psychiatr Neurosci 2003; 28(1): 48-54.
86. Van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program. Soc Psychiatr Epidemiol 2003; 156(4): 319-27.
87. Sevy S, Robinson DG, Holloway S, et al. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 2001; 104(5): 367-74.
88. Miller P, Lawrie SM, Hodges A, et al. Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2001; 36(7): 338-42.
89. Compton MT, Kelley ME, Ramsay CE, et al. Association of preonset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am J Psychiatry 2009; 166(11): 1251-7
90. Hall W, Degenhardt L. Cannabis use and the risk of developing a psychotic disorder. World Psychiatry 2008; 7(2): 68-71.
91. Andreasson S, Allebeck P, Engstrom A, et al. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987; 2: 1483-6.
92. Van Os J, Bak M, Hanssen M, et al. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002; 156(4): 319-27.
93. Henquet C, Krabbendam L, Spauwen J, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005; 330(7481): 11.
94. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med 2003; 33(1): 15-21.
95. Caspi A, Moffitt TE, Cannon M, McClay J, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatr 2005; 57(10): 1117-27.
96. Henquet C, Rosa A, Krabbendam L, et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9- tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology. 2006; 31(12): 2748-57.
97. Zammit S, Spurlock G, Williams H, et al. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatr 2007; 191: 402-7
98. Zammit S. An investigation into the use of cannabis and tobacco as risk factors for schizophrenia. PhD thesis, Cardiff University 2004.
99. Macleod J, Oakes R, Copello A, Crome I, et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 2004; 363(9421): 1579-88.
100. Imade AG, Ebie JC. A retrospective study of symptom patterns of cannabis-induced psychosis. Acta Psychiatr Scand 1991; 83(2): 134-6.
101. Arendt M, Rosenberg R, Foldager L, et al. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry 2005; 187: 510-5.
102. Mathers DC, Ghodse AH. Cannabis and psychotic illness. Br J Psychiatry 1992; 161: 648-53.
103. McGuire PK, Jones P, Harvey I, et al. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 1995; 15(3): 277-81.
104. Talbott JA, Teague JW. Marihuana psychosis. JAMA 1969; 210: 299-302.
105. Kolansky H, Moore WT. Effects of marihuana on adolescents and young adults. JAMA 1971; 216: 486-92.
106. Thacore VR. Bhang psychosis. Br J Psychiatry 1973; 123: 225-9.
107. Thacore VR, Shukla SR. Cannabis psychosis and paranoid schizophrenia. Arch Gen Psychiatry 1976; 33: 383-6.
108. Carney MWP, Bacelle L, Robinson B. Psychosis after cannabis use. BMJ 1984; 288: 1047.
109. Wylie AS. Psychosis due to 'skunk'. BMJ 1995; 311: 125.
110. Basu D, Malhotra A, Bhagat A, et al. Cannabis psychosis and acute schizophrenia. A case-control study from India. Eur Addic Res 1999; 5: 71-3.
111. Bromberg W. Marihuana: a psychiatric study. JAMA 1939; 113: 4-12.
112. Grech A, Van Os J, Jones PB, et al. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry 2005; 20: 349-53.
113. Caspari D. Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci 1999; 249: 45-9.
114. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51(4): 273-9.
115. Arias Horcajadas F, Romero SS, Calo JJP. Relevance of drug use in clinical manifestations of schizophrenia [Spanish]. Actas Esp Psiquiatr 2002; 30: 65-73.
116. Martinez-Arevalo MJ, Calcedo-Ordonez A, Varo-Prieto JR. Cannabis consumption as a prognostic factor in schizophrenia. Br J Psychiatry 1994; 164: 679-81.
117. Zammit S, Moore TH, Lingford-Hughes A, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 2008; 193(5): 357-63.
118. Makkos Z, Fejes L, Inczédy-Farkas G, et al. Psychopharmacological comparison of schizophrenia spectrum disorder with and without cannabis dependency. Prog Neuropsychopharmacol Biol Psychiatry 2010; 35(1): 212-7.
119. Compton MT, Furman AC, Kaslow NJ. Lower negative symptom scores among cannabis-dependent patients with schizophreniaspectrum disorders: preliminary evidence from an African American first-episode sample. Schizophr Res 2004; 71: 61-4.
120. Spencer C, Castle D, Michie PT. Motivations that maintain substance use among individuals with psychotic disorders. Schizophr Bull 2002; 28: 233-47.
121. Connel PH. Amphetamine psychosis. Maudsley monograph n. 5. London: Chapman & Hall 1958.
122. Janowski DS, Risch C. Amphetamine psychosis and psychotic symptoms. Psychopharmacology 1979; 65: 73-7.
123. McLellan AT, Woody GE, O'Brien CP. Development of psychiatric illness in drug abusers. Possible role of drug preference. N Engl J Med 1979; 301: 1310-4.
124. Sato M, Chen CC, Akiyama K, et al. Acute exacerbation of paranoid psychotic state after long term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 1983; 18: 429-40.
125. Flaum M, Schultzs SK. When does amphetamine-induced psychosis become schizophrenia? Am J Psychiatry 1996; 153: 812-5.
126. Stahl SM. Stahl's essential Psychopharmacology. Third edition. Cambridge University Press. 984-985
127. Giros B, Jaber M, Jones SR, et al. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379: 606-12.
128. Iyo M, Nishio M, Itoh T, et al. Dopamine D2 and serotonin S2 receptors in susceptibility to methamphetamine psychosis detected by positron emission tomography. Psychiatr Res 1993; 50: 217-31.
129. Sekine Y, Iyo M, Ouchi Y, et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 2001; 158: 1206-14.
130. Sekine Y, Minabe Y, Ouchi Y, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine related psychiatric symptom. Am J Psychiatry 2001; 158: 377-82.
131. Volkow ND, Chang L, Wang GJ, et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: assotiation with metabolism in the orbitofrontal cortex. Am J Psychiatry 2001; 158: 2015-21.
132. Srisurapanont M, Ali R, Marsden J, et al. Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol 2003; 6(4): 347-52.
133. Mcketin R, McLaren J, Lubman DI, et al. The prevalence of psychotic symptoms among methamphetamine users. Addition 2006; 101: 1473-78.
134. Smith MJ, Thirthalli J, Abdallah AB, et al. Prevalence of psychotic symptom in substance users: a comparison across substances. Compr Psychiatry 2009; 50: 245-50.
135. Mahoney JJ, Kalechstein D, De La Garza R, et al. Presence and persistence of psychotic symptoms in cocaine versus methamphetamine-dependent participants. Am J Addict 2008; 17: 83-98.
136. Hall W, Hando J, Darke S, et al. Psychological mobidity and route of administration among amphetamine users in Sydney, Australia. Addiction 1996; 91: 81-7.
137. Johns A. Psychiatric effects on cannabis. Br J Psychiatry 2001; 178: 16-122.
138. Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry 2004; 185: 196-204.
139. Bell DS. A comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry 1965; 3: 701.
140. Griffith JJ, Oates J, Cavanaugh J. Paranoid episodes induced by drugs. JAMA 1968; 205: 39.
141. Slater E. Book review of Amphetamine Psychosis. Vol 5. London: Oxford University Press 1958.
142. Connel PH. Amphetamine Psychosis. Vol 5. London: Oxford University Press 1958.
143. Angrist B, Sathananthan G, Wilk S, et al. Amphetamine psychosis: behavioural and biochemical aspects. J Psychiatr Res 1974; 11: 13-23.
144. Janowsky DS, Risch C. Amphetamine psychosis and psychotic symptoms. Psychopharmacology 1979; 65: 73-7.
145. Sato M, Chen CC, Akiyama K, et al. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 1983; 18: 429-40.
146. Harris D, Batki SL. Stimulant psychosis: symptom profile and acute clinical course. Am J Addict 2000; 9: 28-37.
147. Batki SL, Harris DS. Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia. Am J Addict 2004; 13: 461-70.
148. Nordahl TE, Salo R, Leaman M. Neuropsychological effect of chronic methamphetamine use on neurotransmitters and cognition; a review. J Neuropsychiatr Clin Neurosci 2003; 15: 317-25.
149. Hermens DF, Lubman DI, Ward PB, Naismith SL, Hickie IB. Amphetamine psychosis: a model for studying the onset and course of psychosis. Med J Aust 2009; 190: S22-S5.
150. Post RM. Cocaine psychosis: a continuum model. Am J Psychiatry 1975; 132: 225-3.
151. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: Version III-The final common pathway. Schizophr Bull 2009; (35)3: 549-62.
152. Brady KT, Lydiard RB, Malcom R, Ballenger JC. Cocaine-induced psychosis. J Clin Psychiatry 1991; 52: 509-12.
153. Satel SL, Southwick SM, Gawin FH. Clinical features of cocaineinduced paranoia. Am J Psychiatry 1991; 148: 495-8.
154. Kaye S, Darke S. Injection and non injection cocaine use in Sydney, Australia: physical and psychological morbididy. Drug Alcohol Rev 2004; 23: 391-98.
155. Thirthalli J, Benegal V. Psychosis among substance users. Curr Opin Psychiatry 2006; 19: 239-45.
156. Rosse RB, Collins JP, Fay McCarthy M, et al. Phenomenologic comparison of the idiopathic psychosis of schizophrenia and druginduced cocaine and phencyclidine psychosis: a retrospective study. Clin Neuropharmacol 1994; 17: 359-69.
157. Palermo GB, Palermo MT. Clinical diagnostic considerations on cocaine abuse. J Psychoactive Drug 1990; 22 (3): 313-8.
158. Serper MR, Chou IC, Allen MH, et al. Symptomatic overlap of cocaine intoxication and acute schizophrenia at emergency presentation. Schizophr Bull 1999; 25: 387-94.
159. Shaner A, Roberts LJ, Eckman TA, et al. Source of diagnostic uncertainty for chronically psychotic cocaine abusers. Psychiatr Serv 1998; 49(5): 684-90.
160. Siegel RK. Cocaine smoking disorders: diagnosis and treatment. Psychiatric Ann 1984; 14: 728-32.
161. Gouzoulis E, Daumann J. Neurotoxicty of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 2006; 101(3): 348-61.
162. Hurley RA, Reneman L, Taber KH. Ecstasy in the brain: a model for neuroimaging. J Neuropsychiatr Clin Neurosci 2002; 14(2): 125-9.
163. Verbaten MN. Deterioration of executive functioning in chronic ecstasy users; evidence for multiple drugs effects. Curr Drug Abuse Rev. 2010; 3(3): 129-38.
164. Soar K, Turner JJ D, Parrot AC. Psychiatry disorders in ecstacy (MDMA) users: a literature review focusing on personal predisposition and drug history. Hum Psychopharmacol Clin Exp 2001; 16: 641-5.
165. McGuire PK, Cope H, Fahy TA. Diversity of psychopatology associated with use of 3,4-methylenedioxymethamphetamine (Ecstacy). Br J Psichiatry 1994; 165(3): 391-5.
166. Schifano F, Di Furia L, Forza G, et al. MDMA ('ecstasy') consumption in the contex of polidrug abuse: a report on 150 patients. Drug Alcohol Depend 1998; 52: 85-90.
167. Landabaso MA, Iraurgi I, Jimenez-Lerma JM, et al. Ecstacyinduced psychotic disorder: six-month follow-up study. Eur Addict Res 2002; 8: 133-40.
168. Falck RS, Carlson RG, Wang J, Siegal HSA. Psychiatric disorders and their correlates among young adult MDMA users in Ohio. J Psychoactive Drugs 2006; 38(1): 19-29.
169. Blouin AG, Perez EL, Jane H. Computerized administration of the diagnostic interview schedule. Psychiatr Res 1988; 23(3): 335-44.
170. Zukin RS, Zukin SR. Specific [3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci USA 1979; 76: 5372-6.
171. Johnstone M, Evans V, Baigel S. Sernyl (CI-395) in clinical anaesthesia. Br J Anaesth 1959; 31: 433-9.
172. Luby ED, Cohen BD, Rosembaum G, et al. Study of a new schizophrenomimetic drug-sernyl. Arch Neuro Psychiatry 1959; 81: 363-9.
173. Rosembaum G, Cohen BD, Luby ED, et al. Comparison of sernyl with other drugs: simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (Amytal). Arch Gen Psychiatry 1959; 1: 651-6.
174. Luby ED, Gottlieb JS, Cohen BD, et al. Model psychosis and schizophrenia. Am J Psychiatry 1962; 119: 61-7.
175. Domino E, Luby ED. Abnormal mental state induced by phencyclidine as a model of schizophrenia. In: Domino E, Eds. PCP (phencyclidine): historical and current perspectives, Ann Arbour: NPP Books 1981; pp: 401-18.
176. Yesavage JA, Freeman AM. Acute phencyclidine (PCP) intoxication: psychopathology and prognosis. J Clin Psychiatry 1978; 44: 664-5.
177. Erard R, Luisada PV, Peele R. The PCP psychosis: Prolonged intoxication or drug-precipitated functional illness? J Psychedelic Drugs 1980; 12: 235-45.
178. Krystal JH, Karper LP, Seybil JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry 1994; 51: 199-214.
179. Malhotra AK, Pinals DA, Weingartner K, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 14: 310-07.
180. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995; 6(6): 869-72.
181. Malhotra AK, Pinals DA, Adler CM, et al. Ketamine induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic free-schizophrenics. Neuropsychopharmacology 1997; 17 (3): 141-50.
182. Javitt DC, Zukin SR. Recent advances in phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8.
183. Lathi AC, Weiler MA, Michaelidis T, et al. Effects of ketamine in normal and schizophrenic volonteers. Neuropsychopharmacology 2001; 25: 455-67.
184. Farber NB. The NMDA receptor hypofunction model of psychosis. Ann N J Acad Sci 2003; 1003: 119-30.
185. Krystal JH, Perry EB, Gueorguieva R, et al. Comparative and Interactive human psychopharmaclogic effects of ketamine and amphetamine. Arch gen Psychiatry 2005; 62: 985-95.
186. Pomarol-Clotet E, Honey GD, Murray GK, et al. Psychological effects of ketamine in healthy volunteers. Br J Psychiatry 2006; 189: 173-9.
187. Seeman P, Ko F, Tallerico T. Dopamine receptor contribution to the action of PCP, LSD and Ketamine psychotomimetics. Mol Psychiatry 2005; 10: 877-83.